Description

Pasireotide Acetate CAS NO 396091-76-2 is a synthetic cyclohexapeptide somatostatin analog, formulated as the acetate salt to enhance stability and solubility. This compound is a critical active pharmaceutical ingredient (API) primarily valued for its potent, broad-spectrum binding affinity to somatostatin receptor subtypes. It is essential for pharmaceutical manufacturers and research institutions developing advanced therapeutic solutions for endocrine disorders. The product is supplied under stringent quality controls to ensure batch-to-batch consistency for reliable formulation and research outcomes.

Application

• Pharmaceutical API: Core active ingredient in the manufacture of injectable therapeutics for treating Cushing's disease and acromegaly.
• Oncology Research: Investigated in clinical and preclinical studies for its antiproliferative effects on neuroendocrine tumors (NETs).
• Endocrinology Research: Used as a reference standard and tool compound in studies of somatostatin receptor signaling and hormone secretion regulation.
• Drug Formulation Development: Serves as a key component in the R&D of long-acting release (LAR) depot formulations and other advanced drug delivery systems.
• Analytical Standard: Provides a high-purity benchmark for quality control (QC) and analytical method development (e.g., HPLC, MS) in pharmaceutical laboratories.
• Biochemical Studies: Utilized in receptor binding assays and pharmacological profiling to understand its mechanism of action and selectivity.

Basic Information

Product Name	Pasireotide Acetate
CAS No.	396091-76-2
Molecular Formula	C58H66N10O9 • xC2H4O2
Molecular Weight	1313.41 g/mol (free base)
Synonyms	Pasireotide Acetate; SOM230 Acetate; Cyclo(L-lysyl(2-aminoethylcarbamoyl)-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl) Acetate; (2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-Amino-6-(2-aminoethoxyamino)hexanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoic Acid Acetate; Signifor LAR API
EINECS	Contact for details

Quality Control

Our Pasireotide Acetate is manufactured and tested under a quality management system aligned with ICH Q7 guidelines. Each batch undergoes comprehensive analytical testing to ensure identity, purity, and potency, meeting specifications suitable for pharmaceutical R&D and API use. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting results for key parameters including HPLC assay, related substances, residual solvents, and chiral purity.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or refrigerated (2-8°C) as specified on the label. The product is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccant use and storage under inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (MS)	Conforms to structure
Assay (HPLC)	≥ 98.0% (on anhydrous basis)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Water Content (KF)	≤ 5.0%
Residual Solvents (GC)	Meets ICH Q3C limits
Acetate Content (Titration)	5.0% - 12.0%
Heavy Metals	≤ 20 ppm
Bacterial Endotoxins	< 10 EU/mg

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.